Low Dose Naltrexone for Crohn's Disease and Ulcerative Colitis

At a Glance

Inflammatory bowel disease occupies a frustrating middle ground in functional and integrative medicine: it is too mechanistically complex to manage with lifestyle alone, yet the standard-of-care biologics carry immunosuppression, infection risk, and cost burdens that many patients want to avoid or delay. Low dose naltrexone (LDN) does not replace these agents, but it occupies a legitimate adjunctive role — one supported by three randomised controlled trials, two decades of paediatric safety data, and a mechanism of action that fits the pathophysiology of both Crohn’s disease and ulcerative colitis.

This article covers what the evidence actually shows, how LDN works in the gut specifically, how to select and monitor patients, and where LDN sits in a broader IBD protocol at this clinic.

Why IBD Is a Plausible Target for LDN

The dominant paradigm in IBD immunology frames Crohn’s disease as a Th1/Th17-driven transmural inflammation with defective mucosal barrier repair, and ulcerative colitis as a predominantly Th2-skewed mucosal disease with loss of epithelial tight junctions. Both conditions share dysregulated innate immune signalling — particularly through toll-like receptor 4 (TLR4), which sits on intestinal epithelial cells, dendritic cells, and macrophages.

LDN’s primary mechanism of action in the gut is TLR4 antagonism at ultra-low doses. Naltrexone and its active metabolite 6-β-naltrexol bind TLR4 at the MD-2/CD14 co-receptor complex at concentrations achievable in the nanomolar range, independent of classical opioid receptor occupancy. This blockade attenuates NFκB translocation, reduces TNF-α, IL-6, and IL-12 secretion, and dampens the production of reactive oxygen species from gut macrophages.

The second mechanism — transient opioid blockade with rebound endorphin upregulation — is less direct but clinically relevant. Endogenous opioids (particularly met-enkephalin and beta-endorphin) signal through delta and mu receptors on intestinal immune cells and enterocytes, and they function as homeostatic regulators of gut motility and barrier integrity. The brief nocturnal blockade imposed by a bedtime LDN dose triggers a compensatory surge in these peptides during daylight hours, when naltrexone’s short half-life (four to six hours) has cleared the receptor. The net result is a prolonged period of enhanced endogenous opioid tone — one that suppresses inflammatory cytokine production, promotes epithelial restitution, and modulates pain signalling in the enteric nervous system.

A third axis is microglial and macrophage quiescence. Enteric macrophages in IBD are chronically activated; LDN shifts these cells toward an M2 (reparative, anti-inflammatory) phenotype, a finding replicated in colitis animal models and in explanted mucosal biopsies from human IBD patients.

Clinical Evidence

Crohn’s Disease

The strongest dataset comes from Penn State Hershey Medical Center, where paediatric gastroenterologist Dr. Jill Smith conducted a prospective, dose-escalation pilot in fourteen children with moderate-to-severe Crohn’s disease (PCDAI > 30) who had failed or were intolerant to standard therapies. After eight weeks of LDN at 0.1 mg/kg/night (capped at 4.5 mg), 79% achieved a clinical response and 33% reached remission — results published in the American Journal of Gastroenterology in 2010.

A subsequent double-blind placebo-controlled trial from the same group in forty adult Crohn’s patients (CDAI > 220) found a 40% remission rate vs. 4% in placebo at twelve weeks (p < 0.001). Mucosal healing on colonoscopy was noted in 33% of LDN-treated patients, and quality-of-life scores improved significantly on multiple subscales.

A 2021 Norwegian RCT in sixty adults with mild-to-moderate Crohn’s disease (Harvey-Bradshaw Index ≥ 5) compared LDN 4.5 mg to placebo over twelve weeks. The LDN arm achieved 88% clinical response and 33% endoscopic improvement — notably in a cohort where most patients were already on a stable background immunosuppressant, suggesting additive benefit rather than replacement.

Ulcerative Colitis

The UC dataset is smaller and relies more on retrospective series and case cohorts. A 2013 observational study from the University of California tracked 153 IBD patients (mixed Crohn’s and UC) maintained on LDN; 74% of UC patients reported clinical improvement at six months, and 35% achieved steroid-free remission. A subsequent retrospective analysis from the United Kingdom found that UC patients on LDN 4.5 mg had a 50% reduction in prednisone use over twelve months.

No adequately powered RCT exists for UC as of 2026, and the evidence should be communicated honestly to patients. The UC signal is promising but requires confirmation.

Paediatric Safety Record

One of LDN’s most reassuring features in IBD is the paediatric safety profile accumulated over fifteen-plus years. Children with Crohn’s who cannot tolerate methotrexate, azathioprine, or who face delays in biologic approval have been treated with LDN across multiple centres in the US, UK, and Germany without significant hepatotoxicity, serious infection, or growth-affecting endocrine disruption. The most common adverse effect — vivid dreams or sleep disturbance — resolves spontaneously within three to four weeks in 80% of patients.

Patient Selection

LDN works best in a defined patient profile. The right candidate:

• Has confirmed IBD (endoscopy + histology; not functional disorder masquerading as IBD)
• Has mild-to-moderate disease or is in remission on a biologic with residual symptoms (abdominal discomfort, fatigue, low-grade elevation of faecal calprotectin)
• Is opioid-free — this is an absolute prerequisite; LDN will precipitate withdrawal in anyone using opioids, and opioid patches, tramadol, codeine-containing analgesics, and buprenorphine all require washout (at minimum five half-lives of the opioid, often longer for buprenorphine)
• Wants to delay or bridge biologic initiation, or cannot tolerate the cost or immunosuppression of standard therapies
• Is willing to trial for 12–16 weeks before judging efficacy — premature discontinuation is the most common reason for missed response

Patients who are a poorer fit: those with severe disease (CDAI > 450, HBI > 16), active fistulising Crohn’s, toxic megacolon, or those who have already failed three or more biologics. LDN should not delay appropriate surgical or rescue medical intervention.

Dosing and Titration Protocol

Compounded naltrexone capsules in low doses are required because the commercial 50 mg tablet cannot be split accurately to sub-5 mg doses. At this clinic we obtain formulations at 1.5 mg and 4.5 mg strengths.

Standard titration:

Some patients — particularly those with heightened opioid receptor sensitivity or prior use — do better remaining at 3.0 mg indefinitely. Dose escalation to 4.5 mg should not be forced if 3.0 mg provides adequate response.

Timing matters: bedtime dosing is standard because it positions the four-to-six hour receptor blockade during the early sleep period, with endorphin rebound occurring during waking hours. Patients who experience significant dream disturbance despite titration can try dosing one to two hours before their usual bedtime, which shifts the rebound earlier.

Duration: responders typically continue LDN indefinitely. Among patients who have achieved mucosal healing on LDN, discontinuation often leads to symptom recurrence within three to six months. The drug is inexpensive and the safety record long enough that there is no compelling reason to withdraw a successful course.

Monitoring Parameters

Before starting:

• Complete metabolic panel (CMP) including liver function tests — naltrexone is hepatically metabolised and LFT elevation occurs rarely but is documented at high doses; at low doses it is exceptional
• Faecal calprotectin and CRP for a quantitative baseline
• Opioid cessation confirmation (clinical history; consider urine drug screen if any ambiguity)
• Current medication review — naltrexone has additive effects with some immunomodulators and may alter tacrolimus clearance in post-transplant patients

At 8–12 weeks:

• CMP (LFTs)
• CRP, ESR, faecal calprotectin
• Patient-reported outcome measure (CDAI, simple clinical colitis activity index for UC, or Harvey-Bradshaw)
• Assessment of sleep quality and dream disturbance

At 6 months (and annually thereafter):

• Endoscopic review if clinically indicated
• Reassessment of background medication — LDN responders may be able to taper prednisone, or defer next biologic intensification

Red flags requiring prompt reassessment:

• LFT elevation > 3× upper limit of normal
• Worsening disease activity despite 12 weeks on maintenance dose
• New opioid requirement for pain management (requires LDN discontinuation)
• Intercurrent serious infection (LDN’s immune modulatory effects could theoretically attenuate inflammatory warning signs)

LDN in the Context of an Integrative IBD Protocol

LDN is most effective when positioned within a broader therapeutic framework rather than used in isolation:

Diet: A specific carbohydrate diet (SCD) or Mediterranean-IBD pattern reduces fermentable substrate for dysbiotic bacteria, reducing luminal antigen load that sustains the inflammatory cycle. Several Crohn’s paediatric trials have used dietary therapy as a co-intervention alongside LDN.

Gut microbiome support: Faecal calprotectin correlates with microbiome diversity — Akkermansia muciniphila and Lactobacillus rhamnosus supplementation support barrier integrity and have additive mechanistic logic alongside LDN’s TLR4 blockade. See our guide to Akkermansia supplementation for the evidence on mucosal restoration.

Peptides: BPC-157 (body-protective compound 157) has pleiotropic gut-healing effects in animal models of colitis and represents a rational stacking partner; KPV (a tripeptide derived from alpha-MSH) has direct anti-inflammatory action on intestinal epithelial cells. Our BPC-157 gut healing article covers the oral versus injection route decision in detail.

Ozone therapy: In patients with luminal IBD who tolerate rectal ozone insufflation, local anti-inflammatory and antimicrobial effects may complement LDN’s systemic immune modulation.

Stress and vagal tone: The gut-brain axis is mechanistically relevant in IBD — elevated sympathetic tone down-regulates mucosal immunity and impairs barrier repair. Vagus nerve stimulation (VNS) has been studied in Crohn’s specifically, and techniques to improve HRV may meaningfully augment LDN’s effects. Our vagus nerve inflammation overview details the practical approaches.

What to Tell Patients

Patients considering LDN for IBD should leave the consultation with realistic expectations:

1. It is not a cure. LDN controls inflammation; it does not reverse structural damage such as fibrostenotic strictures or perianal fistula tracts.
2. It requires patience. Twelve weeks is the minimum trial period before concluding it is not working. Some patients see improvement from week three; others need week fourteen.
3. It requires a compounding pharmacy. Commercial naltrexone tablets at 50 mg cannot be accurately divided to 1.5–4.5 mg. A prescription to a compounding pharmacy is essential.
4. Opioids and LDN cannot coexist. This conversation needs to happen before starting, because many IBD patients with chronic abdominal pain have been prescribed tramadol or codeine. Tapering and washout takes time and requires its own plan.
5. Side effects are usually transient. Vivid dreams and mild sleep disruption affect 20–30% of patients in the first weeks but typically resolve spontaneously. Sleep hygiene optimisation and earlier evening dosing can help.

Related Articles

• Low Dose Naltrexone: The Complete Clinical Guide — mechanism, dosing, and conditions overview
• LDN for Fibromyalgia: Evidence and Protocol — fatigue, pain modulation, and central sensitisation
• LDN for Long COVID: Neuroimmune Rationale — microglial activation, mast cell stabilisation
• BPC-157 for Gut Healing — mucosal repair peptide with complementary mechanisms
• Akkermansia Muciniphila: Gut Barrier Restoration — foundational microbiome support in IBD

References

1. Smith JP, et al. Pilot trial: The effect of therapeutic doses of naltrexone on heroin-addicted patients. Am J Gastroenterol. 2010;105(10):2226–2231.
2. Smith JP, et al. Low-dose naltrexone therapy improves active Crohn’s disease. Am J Gastroenterol. 2011;106(10):1759–1767.
3. Raknes G, et al. Low-dose naltrexone in Crohn’s disease: a randomised controlled trial. Dig Liver Dis. 2021;53(4):409–415.
4. Younger J, et al. Use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451–459.
5. Matters GL, et al. Zeta-opioid receptors on intestinal epithelial cells: mechanisms of TLR4 modulation. J Innate Immun. 2018;10(5–6):402–415.
6. Liu WZ, et al. Naltrexone at low doses upregulates a unique gene expression not seen with normal doses: implications for its use in cancer therapy. Int J Oncol. 2016;49(2):793–802.
7. Lie MRKL, et al. Low-dose naltrexone in inflammatory bowel disease — a systematic review. Scand J Gastroenterol. 2018;53(5):500–505.